Photoactivation of endogenous porphyrins for treatment of psoriasis
US6269818A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 26, 1998 |
| Grant date | Aug 7, 2001 |
| Priority date | — |
| Expiry date | May 26, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N5/062
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In one aspect, the invention provides a diagnostic method for identifying psoriatic plaques in which Porphyrins, particularly protoporphyrin IX, are elevated as compared to normal skin and skin of patients with other dermatological diseases, including other forms of psoriatic plaque. Psoriatic plaques with elevated porphyrin levels may be detected by fluorescence and spectral analysis. Endogenous porphyrins in psoriatic plaques may be activated with visible light to treat psoriatic plaques having elevated porphyrin concentrations. Skin conditions may be optimized to increase the endogenous concentration of porphyrins in psoriatic plaques. A topical formulation may be applied to psoriatic plaques to optimize skin conditions such as pH, iron concentration, temperature, hydration, calcium concentration, oxygenation, electrical conductivity and estrogen concentration to increase the concentration of endogenous porphyrins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.